SCHEMBL18201167

SCHEMBL18201167

c1ccc2cc(-c3cc(-c4ccc5ccccc5c4)nc(-c4ccc(-c5ccc(-c6cc7c(-c8ccc9ccccc9c8)nc8ccccc8c7c7ccccc67)cc5)cc4)n3)ccc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A1 P04798 1/20 0.42
CYP1B1 Q16678 1/20 0.42
ACACA Q13085 3/20 0.40
CYP1A2 P05177 3/20 0.40
BTK Q06187 1/20 0.38
MEN1 O00255 5/20 0.37
KMT2A Q03164 5/20 0.37
ATM Q13315 2/20 0.37
CTRC Q99895 1/20 0.36
ALDH1A1 P00352 5/20 0.36
HPGD P15428 4/20 0.36
NPSR1 Q6W5P4 2/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
MAPT P10636 3/20 0.36
KDM4E B2RXH2 3/20 0.36
HTR2B P41595 1/20 0.36
HTR5A P47898 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
PIM1 P11309 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18200553 0.99 CYP1A1 (0.43) CYP1A1CYP1B1ACACACYP1A2BTK
SCHEMBL18201179 0.96 ACACA (0.45) CYP1A1CYP1B1ACACACYP1A2MEN1
SCHEMBL18201214 0.96 ACACA (0.45) CYP1A1CYP1B1ACACACYP1A2MEN1
SCHEMBL18200555 0.96 ACACA (0.45) CYP1A1CYP1B1ACACACYP1A2MEN1
SCHEMBL18346981 0.96 ACACA (0.45) CYP1A1CYP1B1ACACACYP1A2MEN1
SCHEMBL18200556 0.96 ACACA (0.45) CYP1A1CYP1B1ACACACYP1A2MEN1
SCHEMBL18200565 0.96 ACACA (0.45) CYP1A1CYP1B1ACACACYP1A2MEN1
SCHEMBL18200426 0.96 ACACA (0.45) CYP1A1CYP1B1ACACACYP1A2MEN1
SCHEMBL18200559 0.96 ACACA (0.45) CYP1A1CYP1B1ACACACYP1A2MEN1
SCHEMBL18200891 0.96 ACACA (0.45) CYP1A1CYP1B1ACACACYP1A2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9728731-B2 Heterocyclic compound and organic light emitting device using same HEESUNG MATERIAL LTD. (KR) 2017-08-08 US disclosed
US-9728731-B2 Heterocyclic compound and organic light emitting device using same HEESUNG MATERIAL LTD. (KR) 2017-08-08 US disclosed
US-20160380208-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME HEESUNG MATERIAL LTD. (KR) 2016-12-29 US disclosed
EP-3088392-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME Heesung Material Ltd. (KR) 2016-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160380208-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME NOTUM, DDT, CRY1 CYP1A1 84/4885CYP1B1 109/4885ACACA 2979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.